Boston Scientific invests in MValve Technologies

Boston Scientific has closed on an additional round of financing with MValve Technologies, which it has been providing with funding since 2012.

MValve Technologies is working on a percutaneous mitral valve replacement system that is designed to work with the Boston Scientific Lotus Valve, creating a unique mitral regurgitation treatment solution.

With this new financing, a first-in-human clinical trial will be launched for the MValve docking system, assessing its use in transcatheter mitral valve replacement procedures among patients with mitral regurgitation.

Kevin Ballinger, senior vice-president and president of interventional cardiology at Boston Scientific, said: "This round of financing will support the development of the MValve technology in anticipation of a first-in-human clinical trial, and we are pleased to be continuing our collaboration."

Boston Scientific also has an exclusive option to acquire MValve based on the success of its current research. It has identified the transcatheter mitral valve replacement field as a key area for growth.